Abiraterona en cáncer de próstata hormono-sensible metastásico

9 / 32

Better
Worse
7 9 5 3 0 15 17 21 19 23 25 27 29 31 33 2 4 6 8 11 13 10 12 1
0.4
0.2
0.0
-0.2
-0.4
0.6
FACT-P total score
ADT + Placebos ADT + AA + P
Cycle*
338
309
250
192
202
119
135
77
65
33
20
7
0
0
ADT + Placebos, 8.3 mo
Patients without degradation
in FACT-P total score (%)
100
80
60
20
0
40
597
602
0 6 12 18 24 30 36 42
Months
ADT + AA + P, 12.9 mo
HR 0.85 (95% CI, 0.74-0.99)
P = 0.0322
Patients at risk
ADT + AA + P
ADT + Placebos
ADT + AA + P Significantly Improved
HRQoL per FACT-P
15% Risk Reduction
for HRQoL Degradation
Mean Change From Baseline
Differed from Cycle 5 Onward
14
*1 cycle = 28 days.
7 9 5 3 0 15 17 21 19 23 25 27 29 31 33 2 4 6 8 11 13 10 12 1
0.4
0.2
0.0
-0.2
-0.4
0.6
FACT-P total score
ADT + Placebos ADT + AA + P
Cycle*
338
309
250
192
202
119
135
77
65
33
20
7
0
0
ADT + Placebos, 8.3 mo
Patients without degradation
in FACT-P total score (%)
100
80
60
20
0
40
597
602
0 6 12 18 24 30 36 42
Months
ADT + AA + P, 12.9 mo
HR 0.85 (95% CI, 0.74-0.99)
P = 0.0322
Patients at risk
ADT + AA + P
ADT + Placebos
ADT + AA + P Significantly Improved
HRQoL per FACT-P
15% Risk Reduction
for HRQoL Degradation
Mean Change From Baselin
Differed from Cycle 5 Onwa
*1 cycle = 28 days.